Physostigmine for gamma-hydroxybutyrate coma: Inefficacy, adverse events, and review

References

• Henderson RS, Holmes CM. Reversal of the anaesthetic action of sodium gamma-hydroxybutyrate. Anaesth Intensive Care 1976; 4: 351–354
   PubMedGoogle Scholar
• Holmes CM, Henderson RS. The elimination of pollution by a non inhalational technique. Anaesth Intensive Care 1978; 6: 120–124
   PubMed Web of Science ®Google Scholar
• Caldicott DG, Kuhn M. Gamma-hydroxybutyrate overdose and physostigmine: teaching new tricks to an old drug?. Ann Emerg Med 2001; 37: 99–102
   PubMed Web of Science ®Google Scholar
• Yates SW, Viera AJ. Physostigmine in the treatment of gamma-hydroxybutyric acid overdose. Mayo Clin Proc 2000; 75: 401–402
   PubMed Web of Science ®Google Scholar
• Boyce SH, Padgham K, Miller LD, Stevenson J. Gamma hydroxybutyric acid (GHB): an increasing trend in drug abuse. Eur J Emerg Med 2000; 7: 177–181
   PubMedGoogle Scholar
• Chin RL, Sporer KA, Cullison B, Dyer JE, Wu TD. Clinical course of gamma-hydroxybutyrate overdose. Ann Emerg Med 1998; 31: 716–722
   PubMed Web of Science ®Google Scholar
• Dyer JE. Gamma-Hydroxybutyrate: a health-food product producing coma and seizurelike activity. Am J Emerg Med 1991; 9: 321–324
   PubMed Web of Science ®Google Scholar
• Eckstein M, Henderson SO, DelaCruz P, Newton E. Gamma hydroxybutyrate (GHB): report of a mass intoxication and review of the literature. Prehosp Emerg Care 1999; 3: 357–361
   PubMedGoogle Scholar
• Elliott SP. Nonfatal Instances of Intoxication with gamma-Hydroxybutyrate in the United Kingdom. Ther Drug Monit 2004; 26: 432–440
   PubMed Web of Science ®Google Scholar
• Garrison G, Mueller P. Clinical features and outcomes after unintentional gamma hydroxybutyrate (GHB) overdose (Abstract). J Tox Clin Toxicol 1998; 36: 503–504
   Google Scholar
• Harraway T, Stephenson L. Gamma hydroxybutyrate: The Gold Coast Experience. Emerg Med (Australia) 1999; 11: 45–48
   Google Scholar
• Li J, Stokes SA, Woeckener A. A tale of novel intoxication: seven cases of gamma-hydroxybutyric acid overdose. Ann Emerg Med 1998; 31: 723–728
   PubMed Web of Science ®Google Scholar
• Liechti ME, Kupferschmidt H. Gamma-hydroxybutyrate (GHB) and gamma-butyrolactone (GBL): Analysis of overdose cases reported to the Swiss Toxicological Information Centre. Swiss Med Wkly 2004; 134: 534–537
   PubMed Web of Science ®Google Scholar
• Mahon KD, Tomaszewski CA, Tayal VS. Emergency department presentation of serum confirmed GHB ingestions. Acad Emerg Med 1999; 6: 395–396
   Google Scholar
• Miro O, Nogue S, Espinosa G, To-Figueras J, Sanchez M. Trends in illicit drug emergencies: the emerging role of gamma-hydroxybutyrate. J Toxicol Clin Toxicol 2002; 40: 129–135
   PubMed Web of Science ®Google Scholar
• Ryan JM, Stell I. Gamma hydroxybutyrate--a coma inducing recreational drug. J Accid Emerg Med 1997; 14: 259–261
   PubMedGoogle Scholar
• Sporer KA, Chin RL, Dyer JE, Lamb R. Gamma-hydroxybutyrate serum levels and clinical syndrome after severe overdose. Ann Emerg Med 2003; 42: 3–8
   PubMed Web of Science ®Google Scholar
• Van Sassenbroeck DK, Calle PA, Rousseau FM, Verstraete AG, Belpaire FM, Monsieurs KG, Haentjens R, Allonsius J, Van Brantegem J, Haenen W, Buylaert WA. Medical problems related to recreational drug use at nocturnal dance parties. Eur J Emerg Med 2003; 10: 302–308
   PubMed Web of Science ®Google Scholar
• Van Sassenbroeck DK, De Neve N, Debruyne C, Verstraete A, Calle P, Buylaert WA. Illustration of the sudden awakening of gamma-hydroxybutyrate (GHB) associated intoxications (Abstract). J Tox Clin Tox 2004; 42: 478
   Google Scholar
• Williams H, Taylor R, Roberts M. Gamma-hydroxybutyrate (GHB): A new drug of abuse. Irish Med J 1998; 91: 56–57
   PubMedGoogle Scholar
• Zvosec DL, Smith SW, McCutcheon JR, Spillane J, Hall BJ, Peacock EA. Adverse events, including death, associated with the use of 1,4 butanediol. N Engl J Med 2001; 344: 87–94
   PubMed Web of Science ®Google Scholar
• Zvosec DL, Smith SW. Agitation is common in Gamma-hydroxybutyrate toxicity. Am J Emerg Med 2005; 23: 316–320
   PubMed Web of Science ®Google Scholar
• Schneir AB, Offerman SR, Ly BT, Davis JM, Baldwin RT, Williams SR, Clark RF. Complications of diagnostic physostigmine administration to emergency department patients. Ann Emerg Med 2003; 42: 14–19
   PubMed Web of Science ®Google Scholar
• Howland MA. Antidotes in depth: Physostigmine. Goldfrank's Toxicologic Emergencies6^th, LR Goldfrank, NE Flomenbaum, NA Lewin, RS Weisman, MA Howland, RS Hoffman. Appleton and Lange, Stamford, CT 1998; 614–617
   Google Scholar
• Bowden CA, Krenzelok EP. Clinical applications of commonly used contemporary antidotes: A U. S. perspective. Drug Saf 1997; 16: 9–47
   PubMed Web of Science ®Google Scholar
• Smilkstein MJ. Physostigmine. J Emerg Med 1991; 9: 275–277
   PubMedGoogle Scholar
• Traub SJ, Nelson LS, Hoffman RS. Physostigmine as a treatment for gamma-hydroxybutyrate toxicity: A review. J Tox Clin Toxicol 2002; 40: 781–787
   PubMed Web of Science ®Google Scholar
• Mullins ME, Dribben W. Physostigmine treatment of gamma-hydroxybutyric acid overdose: Appropriate or inappropriate use of a reversal agent?. Mayo Clin Proc 2000; 75: 871–873
   PubMed Web of Science ®Google Scholar
• Bania TC, Chu J. Physostigmine does not effect arousal but produces toxicity in an animal model of severe gamma-hydroxybutyrate intoxication. Acad Emerg Med 2005; 12: 185–189
   PubMed Web of Science ®Google Scholar
• Persson B, Henning M. Central cardiovascular effects of gamma-hydroxybutyric acid: interactions with noradrenaline, serotonin, dopamine and acetylcholine transmission. Acta Pharmacol Toxicol (Copenh) 1980; 47: 335–346
   PubMedGoogle Scholar
• Nilsson E. Physostigmine treatment in various drug-induced intoxications. Ann Clin Res 1982; 14: 165–172
   PubMedGoogle Scholar
• Kleinschmidt S, Schellhase C, Mertzlufft F. Continuous sedation during spinal anaesthesia: gamma-hydroxybutyrate vs. propofol. Eur J Anaesthesiol 1999; 16: 23–30
   PubMed Web of Science ®Google Scholar
• Virtue RW, Lund LO, Beckwitt HJ, Vogel JH. Cardiovascular reactions to gamma hydroxybutyrate in man. Can Anaesth Soc J 1966; 13: 119–123
   PubMedGoogle Scholar
• Solway J, Sadove MS. 4-Hydroxybutyrate: a clinical study. Anesth Analg 1965; 44: 532–539
   PubMed Web of Science ®Google Scholar
• Mason PE, Kerns WP. Gamma hydroxybutyric acid (GHB) intoxication. Acad Emerg Med 2002; 9: 730–739
   PubMed Web of Science ®Google Scholar
• Walker WE, Levy RC, Hanenson IB. Physostigmine--its use and abuse. JACEP 1976; 5: 436–439
   PubMedGoogle Scholar
• Newton RW. Physostigmine salicylate in the treatment of tricyclic antidepressant overdosage. JAMA 1975; 231: 941–943
   PubMed Web of Science ®Google Scholar
• Socher M, Eyer F, Felgenhauer N, Zilker T. The Physostigmine Test: An Approach to Anticholinergic Poisonings. (Abstract). J Tox Clin Tox 2003; 41: 414
   Google Scholar
• Pentel PR, Peterson CD. Asystole complicating physostigmine treatment of tricyclic antidepressant overdose. Ann Emerg Med 1980; 9: 588–590
   PubMed Web of Science ®Google Scholar
• Shannon M. Toxicology reviews: Physostigmine. Pediatr Emerg Care 1998; 14: 224–226
   PubMed Web of Science ®Google Scholar
• Maister AH. Atrial fibrillation following physostigmine. Can Anaesth Soc J 1983; 30: 419–421
   PubMedGoogle Scholar
• Boon J, Prideaux PR. Cardiac arrest following physostigmine. Anaesth Intensive Care 1980; 8: 92–93
   PubMed Web of Science ®Google Scholar
• Wax PM. Analeptic use in clinical toxicology: A historical appraisal. J Toxicol Clin Toxicol 1997; 35: 203–209
   PubMed Web of Science ®Google Scholar
• Sakles JC, Laurin EG, Rantapaa AA, Panacek EA. Airway management in the emergency department: a one-year study of 610 tracheal intubations. Ann Emerg Med 1998; 31: 325–332
   PubMed Web of Science ®Google Scholar